Bristol-myers Squibb Compnay

Viiv Healthcare UK (no.5) Limited

Other

Viiv Healthcare UK Limited

Robert G Gentles

Min Ding

Xiaofan Zheng

John A Bender

Piyasena Hewawasam

Scott W Martin

Kap-Sun Yeung

John F Kadow

Thomas W Hudyma

Louis Stanley Chupak

Carl P Bergstrom

Yazhong Huang

Nicholas A Meanwell

Richard Eric Olson

Upender Velaparthi

Katharine A Grant-Young

Yong Tu

Zhong Yang

Jayakumar Sankara Warrier

Ying Han

Prasada Rao Jalagam

Saumya Roy

Makonen Belema

Annapurna Pendri

John S Tokarski

Ivar M McDonald

Bireshwar Dasgupta

Brett R Beno

Chetan Padmakar Darne

Hasibur Rahaman

Gopikishan Tonukunuru

Manjunatha Narayana Rao Kamble

Raju Mannoori

Sivasudar Velaiah

Kotha Rathnakar Reddy

Thiruvenkadam Raja

Feng He

Alan Xiangdong Wang

Guo Li

Shuanghua Hu

Robert A Fridell

Alicia Regueiro-Ren

Gan Wang

Van N Nguyen

Manoranjan Panda

Stephen E Mercer

Srinivasan Thangathirupathy

Shirong Zhu

Rajesh Onkardas Bora

Selvakumar Kumaravel

Ivar M Mcdonald

Mallikarjuna Rao Mettu

Denise Christine Grunenfelder

Michael Wichroski

Shilpa Maheshwarappa Holehatti

Disclosed are compounds of Formula (I): or a salt thereof, wherein: X is CRor N; Y is CRor N; R, R, R, R, R, R, R, and m are defined herein. Also disclosed are methods of using such compounds to inhibit the activity of one or both of diacylglycerol kinase alpha (DGKα) and diacylglycerol kinase zeta (DGKζ), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.

Substituted bicyclic compounds useful as T cell activators

Disclosed are compounds of Formula (I): or a salt thereof, wherein: R, R, R, and Rare defined herein. Also disclosed are methods of using such compounds to inhibit the activity of one or both of diacylglycerol kinase alpha (DGK α) and diacylglycerol kinase zeta (DGKζ), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.

Naphthyridinone compounds useful as T cell activators

Disclosed are compounds of Formula (I): or a salt thereof, wherein: R, R, R, R, R, and m are defined herein. Also disclosed are methods of using such compounds to inhibit the activity of one or both of diacylglycerol kinase alpha (DGK&#x3b1;) and diacylglycerol kinase zeta (DGK&#x3b6;), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.

Substituted naphthyridinone compounds useful as T cell activators

Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth: 

Inhibitors of human immunodeficiency virus replication

Compounds of Formula I with activity against HIV, including pharmaceutical compositions and methods for using these compounds in treating human immunodeficiency virus (HIV) infection, are set forth: 

The present disclosure is generally directed to compounds that can inhibit DAGL&#x3b1; and/or &#x3b2; activity, compositions comprising such compounds, and methods for inhibiting DAGL&#x3b1; and/or &#x3b2; activity.

Glycine chroman-6-sulfonamides for use as inhibitors of diacylglycerol lipase

The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.

Compounds for the treatment of hepatitis C

The invention encompasses compounds of formula I, including pharmaceutically acceptable salts, as well as compositions and methods of using these compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.

Compounds for the treatment of Hepatitis C

Growing community of inventors

Wallingford, CT, United States of America

Robert G Gentles